Global Nucleic Acid Therapeutics Cdmo Market Size & Outlook
Global nucleic acid therapeutics cdmo market, 2018-2030 (US$M)
Related Markets
Global nucleic acid therapeutics cdmo market highlights
- The global nucleic acid therapeutics cdmo market generated a revenue of USD 13,533.7 million in 2023 and is expected to reach USD 33,863.6 million by 2030.
- The market is expected to grow at a CAGR (2024 - 2030) of 14% by 2030.
- In terms of segment, rna-based therapies accounted for a revenue of USD 8,898.8 million in 2023.
- Gene Therapy is the most lucrative type segment registering the fastest growth during the forecast period.
- In terms of region, North America was the largest revenue generating market in 2023.
- Country-wise, Norway is expected to register the highest CAGR from 2024 to 2030.
Global data book summary
| Market revenue in 2023 | USD 13,533.7 million |
| Market revenue in 2030 | USD 33,863.6 million |
| Growth rate | 14% (CAGR from 2023 to 2030) |
| Largest segment | Rna-based therapies |
| Fastest growing segment | Gene Therapy |
| Historical data covered | 2018 - 2022 |
| Base year for estimation | 2023 |
| Forecast period covered | 2024 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Gene Therapy, RNA-based Therapies |
Other key industry trends
- In terms of revenue, the North America accounted for 40.2% of the global nucleic acid therapeutics cdmo market in 2023.
- By country, the U.S. is projected to lead the global market in terms of revenue in 2030.
- By country, Norway is the fastest growing regional market and is projected to reach USD 213.3 million by 2030.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Nucleic Acid Therapeutics CDMO Market Scope
Nucleic Acid Therapeutics CDMO Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|
Global nucleic acid therapeutics cdmo market outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to nucleic acid therapeutics cdmo market will help companies and investors design strategic landscapes.
Rna-based therapies was the largest segment with a revenue share of 65.75% in 2023. Horizon Databook has segmented the Global nucleic acid therapeutics cdmo market based on gene therapy, rna-based therapies covering the revenue growth of each sub-segment from 2018 to 2030.
- Global Nucleic Acid Therapeutics CDMO Type Outlook (Revenue, USD Million, 2018-2030)
- Gene Therapy
- RNA-based Therapies
- Global Nucleic Acid Therapeutics CDMO Service Outlook (Revenue, USD Million, 2018-2030)
- Process Development and Optimization
- Manufacturing Services
- Analytical and Quality Control Services
- Others
- Global Nucleic Acid Therapeutics CDMO End Use Outlook (Revenue, USD Million, 2018-2030)
- Pharmaceutical Companies
- Government & Academic Research Institutes
- Biotech Companies
- Global Nucleic Acid Therapeutics CDMO Application Outlook (Revenue, USD Million, 2018-2030)
- Rare Diseases
- Genetic Disorders
- Infectious Diseases
- Others
Reasons to subscribe to Global nucleic acid therapeutics cdmo market databook:
-
Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
-
Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
-
Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
-
Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
-
Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of Global nucleic acid therapeutics cdmo market databook
-
Our clientele includes a mix of nucleic acid therapeutics cdmo market companies, investment firms, advisory firms & academic institutions.
-
30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
-
Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
-
The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of global-level data and insights on the Global nucleic acid therapeutics cdmo market , including forecasts for subscribers. This global databook contains high-level insights into Global nucleic acid therapeutics cdmo market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Partial client list
Global nucleic acid therapeutics cdmo market size, by regions, 2018-2030 (US$M)
Top 10 countries: Nucleic acid therapeutics cdmo market size, 2023 (US$M)
Global nucleic acid therapeutics cdmo market share, by type, 2023 & 2030 (%, US$M)
Nucleic acid therapeutics cdmo market: Opportunity assessment by country
Global nucleic acid therapeutics cdmo market, by region, 2023 (US$M)
Related industry reports
Related regional statistics
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
